Search Results - Jonathan Cebon

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature by Ashray Gunjur, Oliver Klein, Damien Kee, Jonathan Cebon

    Published in Journal for ImmunoTherapy of Cancer (2019-09-01)
    Get full text
    Article


  2. 2

    PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation by Candani S. A. Tutuka, Miles C. Andrews, John M. Mariadason, Paul Ioannidis, Christopher Hudson, Jonathan Cebon, Andreas Behren

    Published in Molecular Cancer (2017-06-01)
    Get full text
    Article


  3. 3

    PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma by Sagun Parakh, Sagun Parakh, Sagun Parakh, Ashan Musafer, Ashan Musafer, Sabrina Paessler, Tom Witkowski, Tom Witkowski, Connie S. N. Li Wai Suen, Candani S. A. Tutuka, Matteo S. Carlino, Matteo S. Carlino, Alexander M. Menzies, Alexander M. Menzies, Richard A. Scolyer, Richard A. Scolyer, Richard A. Scolyer, Jonathan Cebon, Jonathan Cebon, Jonathan Cebon, Alexander Dobrovic, Alexander Dobrovic, Georgina V. Long, Georgina V. Long, Georgina V. Long, Oliver Klein, Oliver Klein, Andreas Behren, Andreas Behren, Andreas Behren

    Published in Frontiers in Immunology (2021-06-01)
    Get full text
    Article


  4. 4

    Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538 by Oliver Klein, Clare Senko, Matteo S Carlino, Ben Markman, Louise Jackett, Bo Gao, Caroline Lum, Damien Kee, Andreas Behren, Jodie Palmer, Jonathan Cebon

    Published in OncoImmunology (2021-01-01)
    Get full text
    Article


  5. 5

    Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial by Linda Mileshkin, Ben Markman, Oliver Klein, Damien Kee, Jonathan Cebon, Andreas Behren, Matteo Carlino, Bo Gao, Jessica da Gama Duarte, Luke Quigley, Louise Jackett, Richelle Linklater, Andrew Strickland, Clare Scott, Jodie Palmer

    Published in Journal for ImmunoTherapy of Cancer (2021-11-01)
    Get full text
    Article


  6. 6

    A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen. by Rona Y Zhao, Nicole A Mifsud, Kun Xiao, Kok-Fei Chan, Sara Oveissi, Heather M Jackson, Nektaria Dimopoulos, Philippe Guillaume, Ashley J Knights, Tamara Lowen, Neil C Robson, Sarah E Russell, Emmanuel Scotet, Ian D Davis, Eugene Maraskovsky, Jonathan Cebon, Immanuel F Luescher, Weisan Chen

    Published in PLoS ONE (2012-01-01)
    Get full text
    Article


  7. 7

    Frequent MAGE mutations in human melanoma. by Otavia L Caballero, Qi Zhao, Donata Rimoldi, Brian J Stevenson, Suzanne Svobodová, Sylvie Devalle, Ute F Röhrig, Anna Pagotto, Olivier Michielin, Daniel Speiser, Jedd D Wolchok, Cailian Liu, Tanja Pejovic, Kunle Odunsi, Francis Brasseur, Benoit J Van den Eynde, Lloyd J Old, Xin Lu, Jonathan Cebon, Robert L Strausberg, Andrew J Simpson

    Published in PLoS ONE (2010-01-01)
    Get full text
    Article


Search Tools: